Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — E&P Small Cap Healthcare Conference 2024
25 slides from Racura Oncology's conference presentation, Sep 26, 2024
Slide 1: Race to Present at E&P Small Caps Healthcare Conference
ASX Announcement Race to Present at E&P Small Caps Healthcare Conference 26 September 2024 – Race Oncology Limited (“Race”) is pleased to share a copy of the presentation that will be given by Race’s Executive Chair, Dr Pete Smith, at the E&P Small Cap Healthcare Conference in Sydney today. The pres
Slide 2: Race encourages all investors to go paperless by registering their details with the Company’s
Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au. Release authorised by: Media contact: Pete Smith, Executive Chair Jane Lowe +61 411 117 774 info@raceoncology.com jane.lowe@irdepartmen
Slide 3: At the Heart of Cancer Care
S e p t e m b e r 2 0 2 4 AT THE HEART OF CANCER CARE Pete Smith PhD, Executive Chair E&P Small Cap Healthcare Conference 0 1 ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
Slide 4: Important Notice and Disclaimer
Important Notice and Disclaimer A T T H E The material in this presentation has been prepared by Race Oncology Limited (ACN 149 318 749) (Company). H E A R T THIS IS NOT A PROSPECTUS This presentation is not a prospectus, product disclosure statement or disclosure document for the purposes of the Co
Slide 5: Corporate snapshot
Corporate snapshot A T T H E Race Oncology is an ASX-listed, clinical stage biopharmaceutical company with a dedicated mission to be at the H E A R T heart of cancer care. O F C A N C E R Key Data Race 12-month trading history C A R E ASX code RAC Share price $1.74 1 Market capitalisation $296.5m 1
Slide 6: Race Oncology Board
Race Oncology Board A T T H E H E A R T O F C A N C E R C A R E Dr Daniel Tillett, PhD Dr Peter Smith, PhD Dr Serge Scrofani, PhD MBA Managing Director / CEO Executive Chair Non-Executive Director • Former CSO and Executive Director • >30 years' experience in • >28 years’ experience in of Race Oncol
Slide 7: Race Oncology Management Team
Race Oncology Management Team A T T H E H E A R T O F C A N C E R C A R E Dr Daniel Tillett, PhD Dr Michelle Rashford, MBBS Dr Sophia Moscovis, PhD Prof Michael Kelso, PhD Dr Marinella Messina, PhD Managing Director / CEO Chief Medical Officer Vice President Vice President of Research Vice President
Slide 8: Cancer survivorship
6 A T T H E H E A R T O F C A N C E R C A R E survivorship Cancer
Slide 9: Cancer survivorship – life after treatment
Cancer survivorship – life after treatment A T T H E H E A R T New specialties such as cardio- In 2022, there were 18m cancer survivors oncology are focused on reducing Ageing in the US, growing to 22.5m by 2032 1 O F damage caused by treatments Patients receiving chemotherapy have a C A N C E R 37%
Slide 10: Chemotherapy needs improvement
Chemotherapy needs improvement A T T H E H E A R T O F C A N C E R Anthracyclines* are the most widely Current solution – exclude use in used class of chemotherapeutics. high-risk patients and limit C A R E They are highly effective, but can dosing of the drugs cause permanent damage to the cardiova
Slide 11: Anthracycline use is growing
Anthracycline use is growing1, 2, 3 A T T H E Estimated number of anthracycline doses used per year1 H E A R T O F C A N C E R 24.49 22.98 • According to Data Bridge Market 21.55 Research, global anthracycline C A R E 20.22 usage is expected to increase by a 18.97 CAGR of 6.60% between 2023 and 17.7
Slide 12: Anthracyclines continue to be widely used
Anthracyclines continue to be widely used Lymphoma ABVD, CHOP/R-CHOP, DA-EPOCH-R, others Small-cell lung cancer CAV Breast cancer AC/AC-T, FAC/CAF, FEC, others Oesophageal cancer ECF, EOX Acute myeloid leukemia 7+3/DA, ADE Bladder cancer Acute lymphoblastic leukemia Mono (Epi), ECM, Dox + Hyper-CVAD
Slide 13: Clinical development of bisantrene
11 A T T H E H E A R T O F C A N C E R C A R E development of bisantrene Clinical
Slide 14: Bisantrene's history of clinical success
Bisantrene’s history of clinical success A T T H E H E A R T Breast cancer 1 Acute Myeloid Leukaemia O F 471 patients across 9 Phase 2 & 3 Approved in France in 1988, but Lederle (Pfizer) ended C A N C E R clinical trials commercial development of bisantrene due to solubility issues C A R E Less tox
Slide 15: Building on bisantrene's history
Building on bisantrene’s history A T T H E H E A R T Race has… O F • Created RC220, a new formulation of bisantrene which is more soluble C A N C E R and can be delivered intravenously 1 • C A R E RC220 preserves the PK/PD properties of the earlier clinically validated formulations of bisantrene • C
Slide 16: RC220 overcomes significant challenges
RC220 overcomes significant challenges A T T H E H E A R T Bisantrene/RC110 RC220 Comment O F ✓ ✓ C A N C E R Data from 1,500 patients in 50 trials, Clinical efficacy established Approved in France Clinical safety established ✓ ✓ Data from 1,500 patients in 50 trials, C A R E Approved in France Able
Slide 17: Bisantrene + doxorubicin = improved anti-cancer activity
Bisantrene + doxorubicin = A T improved anti-cancer activity 1 T H E H E A R T Bisantrene shows potent cell-killing activity against a diverse range of human cancers when used alone and in combination with doxorubicin, the most commonly used anthracycline O F C A N C E R 10000 Bisantrene IC50 (nM) I
Slide 18: Bisantrene + doxorubicin = protecting the heart
Bisantrene + doxorubicin = protecting the heart 1 A T T H E H E A R T Bisantrene protects the hearts of mice from permanent damage Vehicle caused by the anthracycline, doxorubicin Bisantrene O F Doxorubicin C A N C E R Heart protection was achieved using higher levels of Dox + Bis 1:1 chemotherapy t
Slide 19: Clinical pipeline
Clinical pipeline A T T H E H E A R T O F IND Asset Indication Sponsor Discovery Phase 1 Phase 2 Phase 3 Next milestone enabling C A N C E R Chaim Sheba RC110 Medical Successfully concluded in July C A R E Acute Myeloid Leukaemia Phase 2 Centre, 20241 Israel Cardioprotection + m6A RNA + anti- Race E
Slide 20: RC220 cardioprotection clinical program
RC220 cardioprotection clinical program A T T H E H E A R T An ‘all comers’ Bayesian dose escalation Phase 1a trial of RC220 in any solid tumour patient where anthracycline use is indicated O F Size: 25-50 patients; up to 10 sites in Australia and internationally C A N C E R Sponsor: Race Oncology C
Slide 21: Typical risks in drug development (illustrative)
Typical risks in drug development (illustrative) A T T H E DISCOVERY PRECLINICAL PHASE I PHASE II PHASE III NDA MKT H E A R T Key risks O F Failure to find Lack of preclinical Toxic in man Lack of efficacy Lack of efficacy, emerging Data suitable molecule efficacy or toxicity insufficient C A N C E
Slide 22: Bisantrene market potential – world
Bisantrene market potential – world A T T H E H E A R T Annual revenue generic Annual revenue bisantrene doxorubicin - 20231 cardioprotection + anti-cancer2 O F C A N C E R C A R E US$1.5b US$7b Note: Forecasted revenue reflect a 50% reduction to the physician-stated adoption rate USD$100 base price
Slide 23: Recent & upcoming milestones
Recent & upcoming milestones1 A T T H E H2 CY2023 / H1 CY2024 H2 CY2024 H1 CY2025 H E A R T Interim results released from Sheba 2 O F ✓ study of bisantrene RC110 in AML ✓ Distinguished Oncologist Daniel Von Additional preclinical results on Hoff Joins as Consultant bisantrene mechanism of action C A
Slide 24: Questions
Questions Race Oncology A T T H E H E A R T O F C A N C E R C A R E 22
Slide 25: Contact
Contact PETE SMITH Executive Chairman JANE LOWE Investor & Media Relations +61 2 8051 3043 +61 411 117 774 peter.smith@raceoncology.com jane.lowe@irdepartment.com.au www.raceoncology.com Authorised for release by the Board ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
Race Oncology — E&P Small Cap Healthcare Conference 2024 on 6ix